Clinical features and survival analysis of patients with CD20 positive adult B-lineage acute lymphoblastic leukemia.
- VernacularTitle:CD20阳性成人急性B淋巴细胞白血病患者临床特点及预后相关分析
- Author:
Hao XU
1
,
2
;
Xudong WEI
1
;
Qingsong YIN
1
;
Ping WANG
1
;
Ruihua MI
1
;
Hao AI
1
;
Xiaojiao WANG
1
;
Yufu LI
1
;
Xinghu ZHU
1
;
Yanli ZHANG
1
;
Yongping SONG
1
;
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antigens, CD20; Cell Lineage; Disease-Free Survival; Humans; Leukocyte Count; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis
- From: Chinese Journal of Hematology 2015;36(1):4-9
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical and survival significance of CD20 positive adult patients with B-lineage acute lymphoblastic leukemia (B-ALL).
METHODSThe clinical features and survival of 168 adult patients with B-ALL diagnosed and treated in our department from May 2007 to July 2011 were analyzed retrospectively, 58 expressed CD20 and 110 not.
RESULTSThe sex, distribution of age, anemia, thrombocytopenia, infiltration of liver, spleen and lymph nodes, the expression of myeloid lineage marker, incidence of Ph chromosome, complete remission within 4 weeks showed no significant differences in CD20 positive and negative groups (P>0.05); median white blood cell count at diagnosis and the rate of patients with high white blood cell count in CD20 positive group were 19.2×10⁹/L and 37.9% respectively, which were significantly higher than those of 6.93 × 10⁹/L and 20.9% in CD20 negative group (P<0.05); cumulative incidence of relapse between two groups showed significant difference (P<0.05); multivariable analysis for overall survival and progress-free survival identified CD20 positivity as independent predictor.
CONCLUSIONThe expression of CD20 in adult patients with B-ALL appeared to be associated with high white blood cell count and poor prognosis.
